A Phase I/IIa Study of SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients
Phase of Trial: Phase I/II
Latest Information Update: 20 Sep 2018
At a glance
- Drugs SV-BR-1-GM breast cancer vaccine BriaCell Therapeutics (Primary) ; Cyclophosphamide; Interferon alpha-2b
- Indications Advanced breast cancer
- Focus Adverse reactions; Proof of concept
- Sponsors BriaCell Therapeutics Corp
- 10 Sep 2018 Planned End Date changed from 1 Mar 2020 to 1 Mar 2019.
- 10 Sep 2018 Planned primary completion date changed from 1 Feb 2020 to 1 Feb 2019.
- 08 Aug 2018 According to a BriaCell Therapeutics media release, Cancer Center of Kansas (CCK) has been added as a new clinical trial site for this trial and Dr. Shaker R. Dakhil will be the principal investigator at this site.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History